{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T07:44:37Z","timestamp":1791531877644,"version":"4.3.4"},"reference-count":19,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2022,2,4]],"date-time":"2022-02-04T00:00:00Z","timestamp":1643932800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R03AI144636"],"award-info":[{"award-number":["R03AI144636"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R21AI151363"],"award-info":[{"award-number":["R21AI151363"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"University of Pittsburgh Department of Medicine"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,9,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>We report the emergence of imipenem-relebactam nonsusceptible Pseudomonas aeruginosa in 5 patients treated for nosocomial pneumonia for 10\u201328 days. Genome sequence analysis identified treatment-emergent mutations in MexAB-OprM and\/or MexEF-OprN efflux operons that arose independently in each patient across distinct P. aeruginosa sequence types. Testing with efflux-inhibitor PA\u03b2N restored imipenem-relebactam susceptibility.<\/jats:p>","DOI":"10.1093\/cid\/ciac097","type":"journal-article","created":{"date-parts":[[2022,2,4]],"date-time":"2022-02-04T20:12:38Z","timestamp":1644005558000},"page":"710-714","source":"Crossref","is-referenced-by-count":55,"title":["Evolution of Imipenem-Relebactam Resistance Following Treatment of Multidrug-Resistant <i>Pseudomonas aeruginosa<\/i> Pneumonia"],"prefix":"10.1093","volume":"75","author":[{"given":"Ryan K","family":"Shields","sequence":"first","affiliation":[{"name":"Department of Medicine, University of Pittsburgh , Pittsburgh, Pennsylvania , USA"},{"name":"XDR Pathogen Laboratory, University of Pittsburgh Medical Center , Pittsburgh, Pennsylvania , USA"},{"name":"Antibiotic Management Program, University of Pittsburgh Medical Center , Pittsburgh, Pennsylvania , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madison E","family":"Stellfox","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Pittsburgh , Pittsburgh, Pennsylvania , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen G","family":"Kline","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Pittsburgh , Pittsburgh, Pennsylvania , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Palash","family":"Samanta","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Pittsburgh , Pittsburgh, Pennsylvania , USA"},{"name":"Antibiotic Management Program, University of Pittsburgh Medical Center , Pittsburgh, Pennsylvania , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daria","family":"Van Tyne","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Pittsburgh , Pittsburgh, Pennsylvania , USA"},{"name":"Center for Evolutionary Biology and Medicine, University of Pittsburgh , Pittsburgh, Pennsylvania , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,2,4]]},"reference":[{"key":"2023020110334377900_CIT0001","doi-asserted-by":"crossref","DOI":"10.15620\/cdc:82532","volume-title":"Antibiotic resistance threats in the United States, 2019","author":"Centers for Disease Control and Prevention.","year":"2019"},{"key":"2023020110334377900_CIT0002","doi-asserted-by":"crossref","first-page":"e00875\u201317","DOI":"10.1128\/AAC.00875-17","article-title":"Multicenter evaluation of ceftazidime-avibactam and ceftolozane-tazobactam inhibitory activity against meropenem-nonsusceptible pseudomonas aeruginosa from blood, respiratory tract, and wounds.","volume":"61","author":"Grupper","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2023020110334377900_CIT0003","doi-asserted-by":"crossref","first-page":"e4599","DOI":"10.1093\/cid\/ciaa1306","article-title":"Modifiable risk factors for the emergence of ceftolozane-tazobactam resistance.","volume":"73","author":"Tamma","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2023020110334377900_CIT0004","doi-asserted-by":"crossref","first-page":"e00084\u201321","DOI":"10.1128\/AAC.00084-21","article-title":"In vitro susceptibility of multidrug-resistant Pseudomonas aeruginosa following treatment-emergent resistance to ceftolozane-tazobactam.","volume":"65","author":"Rubio","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"2023020110334377900_CIT0005","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1186\/s12866-019-1522-7","article-title":"In vitro studies evaluating the activity of imipenem in combination with relebactam against Pseudomonas aeruginosa.","volume":"19","author":"Young","year":"2019","journal-title":"BMC Microbiol"},{"key":"2023020110334377900_CIT0006","doi-asserted-by":"crossref","first-page":"e4539","DOI":"10.1093\/cid\/ciaa803","article-title":"A randomized, double-blind, multicenter trial comparing efficacy and safety of imipenem\/cilastatin\/relebactam versus piperacillin\/tazobactam in adults with hospital-acquired or ventilator-associated bacterial pneumonia (RESTORE-IMI 2 study).","volume":"73","author":"Titov","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2023020110334377900_CIT0007","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1093\/cid\/ciz530","article-title":"RESTORE-IMI 1: A multicenter, randomized, double-blind trial comparing efficacy and safety of imipenem\/relebactam vs colistin plus imipenem in patients with imipenem-nonsusceptible bacterial infections.","volume":"70","author":"Motsch","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2023020110334377900_CIT0008","volume-title":"Performance Standards for Antimicrobial Susceptibility Testing","author":"Clinical and Laboratory Standards Institute.","year":"2020","edition":"30"},{"key":"2023020110334377900_CIT0009","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.ijantimicag.2011.08.005","article-title":"Prevalence of efflux-mediated ciprofloxacin and levofloxacin resistance in recent clinical isolates of Pseudomonas aeruginosa and its reversal by the efflux pump inhibitors 1-(1-naphthylmethyl)-piperazine and phenylalanine-arginine-beta-naphthylamide.","volume":"39","author":"Sonnet","year":"2012","journal-title":"Int J Antimicrob Agents"},{"key":"2023020110334377900_CIT0010","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/1471-2164-9-75","article-title":"The RAST server: rapid annotations using subsystems technology.","volume":"9","author":"Aziz","year":"2008","journal-title":"BMC Genomics"},{"key":"2023020110334377900_CIT0011","doi-asserted-by":"crossref","first-page":"106196","DOI":"10.1016\/j.ijantimicag.2020.106196","article-title":"Pseudomonas aeruginosa epidemic high-risk clones and their association with horizontally-acquired beta-lactamases: 2020 update.","volume":"56","author":"Del Barrio-Tofino","year":"2020","journal-title":"Int J Antimicrob Agents"},{"key":"2023020110334377900_CIT0012","first-page":"e00084\u201321","article-title":"Activity of imipenem-relebactam against a large collection of pseudomonas aeruginosa clinical isolates and isogenic beta-lactam-resistant mutants.","volume":"65","author":"Fraile-Ribot","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"2023020110334377900_CIT0013","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1128\/CMR.00040-09","article-title":"Antibacterial-resistant Pseudomonas aeruginosa: clinical impact and complex regulation of chromosomally encoded resistance mechanisms.","volume":"22","author":"Lister","year":"2009","journal-title":"Clin Microbiol Rev"},{"key":"2023020110334377900_CIT0014","doi-asserted-by":"crossref","first-page":"2508","DOI":"10.1093\/jac\/dkaa206","article-title":"In vitro dynamics and mechanisms of resistance development to imipenem and imipenem\/relebactam in Pseudomonas aeruginosa.","volume":"75","author":"Gomis-Font","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"2023020110334377900_CIT0015","doi-asserted-by":"crossref","first-page":"665759","DOI":"10.3389\/fcimb.2021.665759","article-title":"The building blocks of antimicrobial resistance in pseudomonas aeruginosa: implications for current resistance-breaking therapies.","volume":"11","author":"Langendonk","year":"2021","journal-title":"Front Cell Infect Microbiol"},{"key":"2023020110334377900_CIT0016","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1128\/AAC.48.4.1320-1328.2004","article-title":"Enhancement of the mexAB-oprM efflux pump expression by a quorum-sensing autoinducer and its cancellation by a regulator, MexT, of the mexEF-oprN efflux pump operon in Pseudomonas aeruginosa.","volume":"48","author":"Maseda","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"2023020110334377900_CIT0017","doi-asserted-by":"crossref","first-page":"16463","DOI":"10.1038\/s41598-018-34694-z","article-title":"Interplay between MexAB-OprM and MexEF-OprN in clinical isolates of Pseudomonas aeruginosa","volume":"8","author":"Horna","year":"2018","journal-title":"Sci Rep"},{"key":"2023020110334377900_CIT0018","doi-asserted-by":"crossref","first-page":"5084","DOI":"10.1128\/AAC.02556-14","article-title":"The Pseudomonas aeruginosa CreBC two-component system plays a major role in the response to beta-lactams, fitness, biofilm growth, and global regulation.","volume":"58","author":"Zamorano","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"2023020110334377900_CIT0019","doi-asserted-by":"crossref","first-page":"e0008921","DOI":"10.1128\/AAC.00089-21","article-title":"Emergence of resistance to novel cephalosporin-beta-lactamase inhibitor combinations through the modification of the pseudomonas aeruginosa MexCD-OprJ efflux pump.","volume":"65","author":"Gomis-Font","year":"2021","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciac097\/42600761\/ciac097.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/75\/4\/710\/49017993\/ciac097.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/75\/4\/710\/49017993\/ciac097.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T21:56:37Z","timestamp":1675288597000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/75\/4\/710\/6522966"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,4]]},"references-count":19,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2022,2,4]]},"published-print":{"date-parts":[[2022,9,10]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciac097","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,8,15]]},"published":{"date-parts":[[2022,2,4]]}}}